Caplacizumab: First Global Approval

Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the E...

Descripción completa

Detalles Bibliográficos
Autor principal: Duggan, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280848/
https://www.ncbi.nlm.nih.gov/pubmed/30298461
http://dx.doi.org/10.1007/s40265-018-0989-0
Descripción
Sumario:Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the EU for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. This article summarizes the milestones in the development of caplacizumab leading to this first approval.

Ejemplares similares